Skip to main content
Clinical Trials/NL-OMON44326
NL-OMON44326CompletedNot Applicable

Genes involved in the induction and resolution of eczema using the Atopy Patch Test as an in vivo model for atopic dermatitis - APT and markers for eczema

niversitair Medisch Centrum Utrecht0 sites10 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
10

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Observational

Eligibility Criteria

Ages
18 to 99 (—)

Inclusion Criteria

  • age 18-70 years
  • positive APT

Exclusion Criteria

  • Active AE on the patients back
  • - Not sensitized to aeroallergens, such as house dust mite (demonstrated by a positive immuno CAP test for these allergens)
  • - Treatment with systemic immunosuppressive medication (including corticosteroids and cyclosporin) within the 4 weeks prior to having the biopsies performed. In addition, weekly use of equal or more than 50 grams of topical corticosteroids class IV or weekly use of equal or more than 100 grams of topical corticosteroids class III.
  • - Exposure of biopsy location to high levels of UV radiation (e.g. UV-therapy, use of tanning booths, sunbathing) in the 2 weeks prior to taking biopsies
  • - Use of antihistamines in the week or days before and during the APT ( see patientinformation 'Bijlage 4: medicatielijst')

Investigators

Sponsor
niversitair Medisch Centrum Utrecht

Similar Trials